PMV Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- PMV Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Princeton
- Headquarters state / province
- New Jersey
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- PMVP
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001699382
- EIN
- 46-3218129
Board of directors
-
Arnold J. Levine · DirectorSince 2023
-
Carol Giltner Gallagher · DirectorSince 2023
-
Charles M. Baum · DirectorSince 2023
-
David Henry Mack · Director · President and CEOSince 2023
-
Kirsten Flowers · DirectorSince 2023
-
Laurie Stelzer · DirectorSince 2023
-
Richard A. Heyman · DirectorSince 2023
Chief executives
David Henry Mack
· President and CEO
Dates unknown
Director election results
Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
51.3%
-
71.5%
Board connections
4 of this board's directors also sit on 7 other boards.
- via Charles M. Baum
- via Carol Giltner Gallagher
- via Richard A. Heyman
- via Laurie Stelzer
- via Richard A. Heyman
- via Laurie Stelzer
- via Laurie Stelzer
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $1,520,000
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 27, 2025 | David Henry Mack Director, Officer (President and CEO) | Option exercise | +220,643 | $1.37 | $302,281 |
| Oct 23, 2025 | OrbiMed Capital GP V LLC 10% owner | Open-market sale | −1,000,000 | $1.52 | $1,520,000 |
| Sep 10, 2025 | ORBIMED ADVISORS LLC 10% owner | Open-market sale | −500,000 | $1.80 | $900,000 |
| Jul 1, 2025 | Ticktin Robert Officer (General Counsel & COO) | Open-market sale | −23,151 | $1.06 | $24,540 |
| Jul 1, 2025 | Jalota Deepika Officer (Chief Development Officer) | Open-market sale | −33,065 | $1.06 | $35,049 |
| Jul 1, 2025 | Carulli Michael Officer (Chief Financial Officer) | Open-market sale | −28,249 | $1.06 | $29,944 |
| Jul 1, 2025 | David Henry Mack Director, Officer (President and CEO) | Open-market sale | −58,411 | $1.06 | $61,916 |
| Jan 3, 2025 | David Henry Mack Director, Officer (President and CEO) | Option exercise | +17,709 | $0.53 | $9,386 |
| Dec 3, 2024 | David Henry Mack Director, Officer (President and CEO) | Option exercise | +91,750 | $0.53 | $48,628 |
| Sep 11, 2024 | Jalota Deepika Officer (Chief Development Officer) | Open-market sale | −7,218 | $1.50 | $10,827 |
| Sep 11, 2024 | Carulli Michael Officer (Chief Financial Officer) | Open-market sale | −2,891 | $1.50 | $4,337 |
| Jan 18, 2024 | Jalota Deepika Officer (Chief Development Officer) | Grant or award | +95,555 | — | — |
| Jan 18, 2024 | Carulli Michael Officer (Chief Financial Officer) | Grant or award | +82,220 | — | — |
| Jan 18, 2024 | David Henry Mack Director, Officer (President and CEO) | Grant or award | +163,890 | — | — |
| Nov 22, 2023 | OrbiMed Genesis GP LLC 10% owner | Open-market sale | −87,786 | $2.23 | $195,763 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.